Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAKEI V randomized carboplatin versus cisplatin trial in extracranial malignant germ cell tumors
2016-001784-36Phase 3Active
- Sponsor
- University of Bonn
- Start
- Apr 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, cisplatin, etoposide and ifosfamide in germ cell tumor (GCT) (2 arms), sponsored by University of Bonn. Primary endpoint: Event-free survival from randomization. Started Apr 2019; status: active.
02
Drugs
carboplatincisplatinetoposideifosfamide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2016-001784-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001784-36.